Ambrisentan

Hospital Pharmacy

Volumn 42, Issue 12, 2007, Pages 1145-1154

  Cada, Dennis J ^c   Levien, Terri ^a   Baker, Danial E ^a,b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Drug Information Center

^c Washington State University Spokane ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DIGOXIN; DIURETIC AGENT; ILOPROST; LETAIRIS; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNCLASSIFIED DRUG; UNIPROST;

ABDOMINAL PAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MANUFACTURE; DRUG MECHANISM; DYSPNEA; EXERCISE; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; LIVER TOXICITY; NOSE CONGESTION; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; TREATMENT OUTCOME;

EID: 39449091075     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1310/hpj4212-1145     Document Type: Review

References (14)

1. Letairis [package insert]. Foster City, CA: Gilead Sciences, Inc; 2007.
2. Tracleer [package insert]. South San Francisco, CA: Actelion Pharmaceuticals US Inc; 2007.
3. Revatio [package insert]. New York: Pfizer Inc; 2006.
4. Vatter H, Zimmermann M, Weyrauch E, et al. Cerebrovascular characterization of the novel nonpeptide endothelin-A receptor antagonist LU 208075. Clin Neuropharmacol. 2003;26(2):73-83.
5. A inhibition? Curr Med Res Opin. 2006;22(12):2567-2574.
6. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2005; 46(2):529-535.
7. Hoeper MM. Drug therapy of pulmonary arterial hypertension: current and future agents. Drugs. 2005;65(10):1337-1354.
8. Galie N, Frost A, Keogh A, et al. Long-term benefits of ambrisentan in patients with pulmonary arterial hypertension: a comparison by etiology and baseline functional class [abstract]. Eur Heart J. 2005;26(suppl):113.
9. Badesch D, Zwicke D, Keogh AM, et al. Long-term benefits of ambrisentan in patients with pulmonary arterial hypertension associated with connective tissue diseases [abstract]. Arthritis Rheum. 2005;52(suppl 9):s166.
10. Oudiz RJ, Torres F, Frost AE, et al. ARIES-1: a placebo-controlled, efficacy and safety study of ambrisentan in patients with pulmonary arterial hypertension [abstract]. Chest. 2006;130(suppl 4):121S.
11. Galie N, Olschewsky H, Ghofrani HA, et al. Ambrisentan improves 6-minute walk distance and decreases brain natriuretic peptide in patients with pulmonary arterial hypertension [abstract]. Eur Heart J. 2006;27(suppl):832.
12. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan rescue therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function abnormalities [abstract]. Chest. 2006;130(suppl 4):254S.
13. Dufton C, Gerber MJ, Yin O, Brandquist C, Ghofrani HA. No clinically relevant pharmacokinetic interactions between ambrisentan and sildenafil [abstract]. Chest. 2006; 130 (suppl 4):254S.
14. Gerber MJ, Dufton C, Pentikis H, Ghofrani HA. Ambrisentan has no clinically relevant effect on the pharmacokinetics or pharmacodynamics of warfarin [abstract]. Chest. 2006; 130(suppl 4):256S.